About Oxyhaler – A New Era in Respiratory Protection

World’s First Antiviral Nasal Inhaler, Tested for Safety and Proven for Efficacy

Dr. Shekhar Vaman Phulpagar
Founder & CEO, Parsik Enterprises
(Patent Holder – Government of India, Patent No. 407186)
At ParsiK Enterprises, we are dedicated to developing innovative and science-backed healthcare solutions that protect and improve lives.
Our flagship product — Oxyhaler — is the world’s first antiviral nasal inhaler, created using patented technology and supported by scientific research.
Oxyhaler has been officially granted a patent by the Government of India (Patent No. 407186), confirming its originality, authenticity, and innovation in respiratory care.
The formulation has been laboratory tested for safety against bacteria, fungi, heavy metals, and carcinogens, and has shown 97.81% efficacy against SARS-CoV-2 and H. influenza viruses.
By improving oxygen saturation (SpO₂) levels within minutes and offering rapid relief from nasal congestion, Oxyhaler supports recovery from ailments such as the common cold, viral pneumonia, asthma, and post-viral complications.
Our mission at Parsik Enterprises is to make safe, effective, and affordable respiratory protection accessible to every individual.
With Oxyhaler, we are redefining the future of respiratory care and building a healthier, safer tomorrow.

What our customers have to say

Add to cart